STATEN ISLAND, N.Y., May 12, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc.  , a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat... | May 12, 2023

Related Keywords

United States , Copenhagen , Køavn , Denmark , Netherlands , America , Holland , Dutch , Davidp Luci , Kevin Garey , Robertg Shawah , Ursula Theuretzbacher , Bob Deluccia , Exchange Commission , Drug Administration , Data Monitoring Committee , Diseases Society Of America , University Of Houston College Pharmacy , Nasdaq , Prnewswire Acurx Pharmaceuticals Inc , Leiden University Medical Center Holland , Exchange Commission On Form , Society Or Healthcare Epidemiology Of America , European Congress , Acurx Pharmaceuticals Inc , Acurx Pharmaceuticals , Trial Oversight Committee , Investigational New Drug Application , Independent Data Monitoring Committee , Annual European Congress , Clinical Microbiology , Infectious Disease , Ibezapolstat Against , Reduced Susceptibility , Houston College , Principal Investigator , Acurx Executive Chairman , Leiden University Medical Center , Dutch Government , Chief Executive Officer , Chief Financial Officer , Ibezapolstat Phase , Bile Acid , Clinical Practice Guidelines , Diseases Society , Healthcare Epidemiology , New England Journal , England Journal , Private Securities Litigation Reform Act , United States Food , Looking Statements , Chief Executive , Nc Stock Exchange , News , Information , Press Release , Utaten , Bay , 023 , Curx , Linical , Stage , Iopharmaceutical , Company , Developing , Few , Glass , F , Antibiotics , Or Acxp Us00510m1045 ,